Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents

Abdel-Rahman Omar; ElHalawani Hesham

首页> 外文期刊>Critical reviews in oncology/hematology >Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents

【24h】

Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents

机译：雷莫昔单抗治疗实体瘤患者发生心血管不良事件的风险：其他VEGF靶向药物的荟萃分析和总结

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: We performed a systematic review and meta-analysis of the risk of cardiovascular adverse events associated with ramucirumab.

机译：背景：我们对与拉莫昔单抗相关的心血管不良事件的风险进行了系统的回顾和荟萃分析。

著录项

来源
《Critical reviews in oncology/hematology》 |2016年第null期|共12页
作者
Abdel-Rahman Omar; ElHalawani Hesham;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Ramucirumab; Hypertension; Bleeding; Thrombosis;

机译：雷米库单抗;高血压;出血;血栓形成;

相似文献

外文文献
中文文献
专利

1. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents [J] . Abdel-Rahman Omar, ElHalawani Hesham Critical reviews in oncology/hematology . 2016,第Null期

机译：雷莫昔单抗治疗实体瘤患者发生心血管不良事件的风险：其他VEGF靶向药物的荟萃分析和总结
2. Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials [J] . Zhao Bin, Zhao Hong, Zhao Jiaxin Frontiers in Medicine . 2019,第2期

机译：血管内皮生长因子受体2靶向剂2-靶向剂治疗癌症患者致命不良事件的发病率和风险：具有随机对照试验的试验顺序分析的META分析
3. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials [J] . TzellosT., KyrgidisA., ZouboulisC.C. Journal of the European Academy of Dermatology and Venereology: JEADV . 2013,第5期

机译：用抗IL-12 / 23生物制剂治疗慢性斑块状牛皮癣的患者发生重大不良心血管事件的风险的重新评估：一项随机对照试验的荟萃分析
4. Identifying Patients at Risk of Major Adverse Cardiovascular Events Using Symbolic Mismatch [C] . Zeeshan Syed, John Guttag Annual conference on Neural Information Processing Systems . 2011

机译：使用符号不匹配来识别有重大心血管不良事件风险的患者
5. The development and evaluation of an adverse drug event risk profile for hospitalized patients taking cardiovascular drugs [D] . Payne, Kattie Bell 1990

机译：住院患者服用心血管药物的不良药物事件风险概况的开发和评估
6. Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials [O] . Bin Zhao, Hong Zhao, Jiaxin Zhao 2019

机译：血管内皮生长因子受体2-靶向药物治疗的癌症患者致命不良事件的发生率和风险：随机对照试验的试验序贯分析的荟萃分析。
7. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials [O] . T. Tzellos, A. Kyrgidis, C. C. Zouboulis 2012

机译：重新评估抗IL-12/23生物试剂治疗慢性斑块牛皮癣的患者主要不良心血管事件的风险：随机对照试验的META分析

Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents

摘要

著录项

相似文献

相关主题

期刊订阅